LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

• DOI: 10.1016/j.annonc.2021.08.2142
• Publication Date: 2021-09-21T22:26:16Z
• Authors: L. Paz-Ares; Y. Chen; N. Reinmuth; K. Hotta; D. Trukhin; G. Statsenko; M.J. Hochmair; M. Ozguroglu; J.H. Ji; O. Voitko; A. Poltoratskiy; F. Verderame; L. Havel; I. Bondarenko; G. Losonczy; N.V. Conev; H.L. Broadhurst; T. Dalvi; H. Jiang; J.W. Goldman
• Keywords: 03 medical and health sciences; 0302 clinical medicine